logo
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Business Wire16-07-2025
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic parameters, in vitro evaluation of the inflammatory response in peripheral blood mononuclear cells isolated from study participants, and multiple biomarkers of activity.
'We thank our Investigators and participants for the rapid completion of dosing,' said James Rolke, Chief Executive Officer of Revelation. 'We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.'
About Gemini
Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ®) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner.
Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), or infection post severe burn (GEMINI-PBI). Gemini may also be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program).
Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini: the primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity, as observed through expected changes in multiple biomarkers including upregulation of IL-10.
About CKD
Chronic kidney disease is a pervasive problem in the United States and world-wide. CKD is caused by chronic inflammation and can be initiated and propagated in several ways. One prevalent condition is the high blood sugar levels associated with diabetes (either Type 1 or Type 2): high blood sugar is toxic to kidney cells – it creates stress, which imitates the inflammatory process, leading to the demise of these cells with subsequent fibrosis, ultimately resulting in continuous loss of kidney function over time.
High arterial blood pressure is another source of stress that initiates the inflammatory process that results in CKD. Other risk factors include heart disease, obesity, family history of CKD, or advanced age. Progression of chronic kidney damage often leads to end stage renal disease with the need for renal replacement therapy (dialysis or transplantation), resulting in significant morbidity and mortality for affected patients. Kidney disease is a leading cause of death in the United States.
About AKI
AKI, also known as acute renal failure, is a rapid loss of kidney function. AKI causes a build-up of waste products in the blood, making it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also have a significant impact on other organs, such as the brain, the heart, and the lungs.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, for post-severe burn infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

European Firms Embrace Google Cloud Ecosystem
European Firms Embrace Google Cloud Ecosystem

Business Wire

time27 minutes ago

  • Business Wire

European Firms Embrace Google Cloud Ecosystem

LONDON--(BUSINESS WIRE)--European enterprises are rapidly advancing cloud strategies, often using AI tools and services from the expanding Google Cloud ecosystem, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. European enterprises are adopting agentic AI technologies to extend their capacity to meet the demands of increasingly complex processes. This strategy positions them for enhanced growth opportunities and innovation. Share The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe finds that AI capabilities are helping enterprises use the cloud to enhance operational efficiency and strategic decision-making. For many companies, the AI-powered tools and services in Google Cloud's broad technology suite, especially agentic AI offerings, play a major role in these efforts. 'European enterprises are adopting agentic AI technologies to extend their capacity to meet the demands of increasingly complex processes,' said Dorotea Baljević, director and EMEA industrial AI lead at ISG. 'This strategy positions them for enhanced growth opportunities and innovation.' The focus on using agentic AI to optimize key software development tasks, including code generation and testing, is increasing among European enterprises, the report says. Businesses are leveraging agentic AI for efficient inventory management and personalized product recommendations, driving overall business growth and operational excellence across various industries. There is a growing emphasis on responsible AI in Europe to reduce bias and enhance data security, ISG says. Google Cloud ecosystem providers are supporting these efforts by strengthening AI practices and cybersecurity measures, enabling businesses to confidently navigate the decision-making functions of AI systems while protecting sensitive information across organizational boundaries. This focus ensures ethical AI integration and protects enterprise data against emerging security threats. European enterprises are also adopting data modernization strategies to ensure high-quality, accessible data, which is crucial for agentic AI success, the report says. By migrating legacy data to cloud platforms, businesses gain access to tools that can improve insights and decision-making. Google Cloud ecosystem providers offer expertise in integrating advanced data management, analytics and AI into unified platforms, allowing enterprises to streamline operations and enhance business intelligence. Demand for cloud sovereignty solutions is surging in Europe as enterprises seek to comply with stringent privacy regulations and maintain control over their data systems, ISG says. Enterprises are implementing isolated servers in cloud data centers to address geopolitical uncertainties. Google Cloud ecosystem providers support these efforts by delivering services that ensure independent management of cloud environments, which enhances data security. 'Enterprises are adopting AI and data strategies to enhance productivity while ensuring security and compliance,' said Mark Purdy, principal analyst, ISG Provider Lens Research, and the lead author of the report. 'These initiatives foster growth and operational resilience.' The report also explores other European cloud trends, including the growing adoption of hybrid and multicloud architectures for enhanced flexibility and security and an increasing focus on FinOps for cloud cost optimization and strategic financial management. For more insights into the cloud challenges faced by European enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens ® Focal Points briefing here. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe evaluates the capabilities of 37 providers across four quadrants: Google Cloud Professional Services (Consulting and Migration), Google Cloud Managed Services, Google Cloud Enterprise Data Infrastructure Services and Google Cloud GenAI and AI Services. The report names Accenture, HCLTech, TCS and Wipro as Leaders in all four quadrants. Cognizant, GFT and NTT DATA are named as Leaders in three quadrants each. Atos, LTIMindtree, Quantiphi and T-Systems are named as Leaders in two quadrants each, and DXC Technology, PCG and Telana are named as Leaders in one quadrant each. In addition, Telana is named as a Rising Star — a company with a 'promising portfolio' and 'high future potential' by ISG's definition — in two quadrants. SFEIR is named as a Rising Star in one quadrant. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among Google Cloud ecosystem providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. Customized versions of the report are available from Telana. The 2025 ISG Provider Lens ® Google Cloud Partner Ecosystem report for Europe is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities
Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities

Yahoo

timean hour ago

  • Yahoo

Pony.ai Kicks Off 24/7 Robotaxi Operation in Major Chinese Cities

GUANGZHOU, China, July 25, 2025 /PRNewswire/ -- (NASDAQ: PONY), a global leader in autonomous driving technology, today starts around-the-clock Robotaxi operation in the Chinese megacities of Guangzhou and Shenzhen, two of southern China's dynamic economic engines. This move marks a major step forward in the company's China development, expanding its Robotaxi operation window from 15 hours a day to full 24/7 availability. In the meantime, also extended its Robotaxi testing window in the Chinese capital city of Beijing to 24 hours daily. The initiative builds on extensive operational foundation, with over 50 million kilometers of global autonomous testing. These efforts cover a wide range of traffic and lighting conditions — from midday congestion to late-night driving — providing robust validation of system performance under real-world scenarios. The company's proprietary autonomous driving system — its "virtual driver" — has logged more than 500,000 hours of driverless operation. According to internal metrics, the system has achieved a safety record up to ten times safer than that of human drivers. This continuous validation has sharpened the system's ability to respond to complex road environments and changing weather conditions. At the heart of sensing and perception capabilities is a multi-sensor fusion architecture that integrates high-performance 128-beam LiDAR, 8-megapixel cameras, and 4D imaging millimeter-wave radar. Together, these components deliver real-time, 360-degree perception — even in low-light or nighttime settings. Unlike vision-only systems that rely heavily on ambient light, use of active sensing technologies such as LiDAR and radar adds critical redundancy. This enables the detection of low-contrast objects like pedestrians in dark clothing, reduces the impact of headlight glare, and supports safe navigation on poorly lit or unlit roads. This level of capability is made possible by the company's advanced autonomous driving software stack, built on its "PonyWorld foundation model and virtual driver" architecture. Deployed in its seventh-generation Robotaxi fleet, the system enables stable, high-precision detection of road features, signage, vehicles, and pedestrians — from nearby blind spots to distances of up to 650 meters. To ensure reliability in harsh conditions, the vehicles are also equipped with a proprietary sensor self-cleaning system that mitigates the impact of rain, fog, dusts and road debris. As continues to scale its seventh-generation Robotaxi fleet across Beijing, Shanghai, Guangzhou, and Shenzhen, the company is positioning its always-on trials to help reshape urban transportation. The 24/7 operation initiative underscores commitment to accelerating the commercial viability of Robotaxi services — improving late-night mobility while setting new standards in safety and availability. As cities grow quieter after dark, late-night commuters may find a new kind of travel companion: a safe, reliable Robotaxi — always on, always ready. View original content: SOURCE Sign in to access your portfolio

U.S. Stock Futures Rise But Asia, European Markets Fall on Rate Cut Uncertainty
U.S. Stock Futures Rise But Asia, European Markets Fall on Rate Cut Uncertainty

Wall Street Journal

timean hour ago

  • Wall Street Journal

U.S. Stock Futures Rise But Asia, European Markets Fall on Rate Cut Uncertainty

U.S. stock futures rose after Nasdaq closed at another new record Thursday following Google-parent Alphabet's earnings and despite continued trade tensions and weaker-than-expected housing data. European stocks fell in line with Asia on uncertainty over Fed rate cuts. —U.S. futures for the S&P 500 were up 0.1% and futures for the Dow Jones Industrial Average climbed 0.1%. The S&P 500 added less than 0.1% Thursday for its fourth consecutive record, the longest such streak since December while the tech-heavy Nasdaq gained 0.2% to hit its 12th record of July.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store